Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51

BACKGROUND: A residual risk of ischemic events following an acute coronary syndrome (ACS) remains despite antiplatelet therapy. The addition of an antithrombin as part of a “dual pathway” approach may further improve outcomes as thrombin generation persists for several months post‐ACS. The present s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, William J., Gibson, C. Michael, Yee, Megan K., Korjian, Serge, Daaboul, Yazan, Plotnikov, Alexei N., Burton, Paul, Braunwald, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474929/
http://dx.doi.org/10.1161/JAHA.118.009451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474929/
http://dx.doi.org/10.1161/JAHA.118.009451

Ejemplares similares